Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularMedicationIssue 729

FDA - Stop Using Aspirin for Patients with No History of Heart Disease

The Food and Drug Administration last week stated that aspirin should not be used for stroke or heart attack prevention in people with no history of heart disease.... 

Advertisement

Although evidence indicates that aspirin's benefits outweigh its bleeding risks for patients with a history of a cardiovascular event, the data do not support the use of the drug for the prevention of first heart attack, the agency said. The FDA released the statement in response to Bayer's request to change its aspirin product labeling.

The use of the medicine raises serious risks of bleeding in the stomach and brain, the statement said. While evidence shows that aspirin's benefits for people who have already had a cardiovascular event outweigh the increased risk of bleeding, the data doesn't support using the drug to help people prevent a first attack.

On May 2, the FDA denied a request from Leverkusen, Germany-based Bayer AG to change the labeling on its packaging to market the product for heart-attack prevention for patients with no history of cardiovascular disease. Aspirin generated 916 million euros ($1.27 billion) in sales for Bayer last year.

Anne Coiley, a spokeswoman for Bayer, said in an e-mail, "Importantly, the ruling does not impact the numerous cardiovascular indications for which aspirin is already approved by the FDA."

Aspirin didn't help prevent heart attacks or strokes in people with a high risk of heart disease yet don't show any symptoms, according to a study published in the Journal of the American Medical Association in 2010. Higher-risk people had a similar number of attacks and strokes as participants taking placebo, the researchers said.

Allen Taylor, professor at Georgetown University School of Medicine and chief of cardiology at MedStar Georgetown University Hospital and MedStar Washington Hospital Center, added that, "It's a useful statement to warn people that aspirin is not a blanket therapy."

Practice Pearls:

  • Start the conversation with your patients and question them about their use of aspirin
  • Many patients are taking the daily aspirin due to the quantity of advertising seen
  • Have the conversation about the use of aspirin and the risk versus benefits

FDA News Release, May 5, 2014

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  CardiovascularMedicationIssue 729

Past five issues: Issue 756 | Diabetes Clinical Mastery Series Issue 215 | SGLT-2 Inhibitors Special Edition November 2014 | Issue 755 | GLP-1 Special Editions November 2014 |

2014 Most Popular Articles:

Grapefruit Juice May Affect Insulin Resistance
Posted October 23, 2014
FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-dose Combination
Posted October 23, 2014
New SGLT2 Inhibitor Likely To Be Approved for Type 2 Diabetes
Posted November 14, 2014
What's Hiding in that Insulin Box?
Posted October 27, 2014
Dietary Magnesium Intake's Role in Decreasing Metabolic Syndrome
Posted October 31, 2014
Handbook of Diabetes, 4th Ed., Excerpt #16: Diabetic Neuropathy
Posted November 02, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014
Very Low Carbohydrate, Low Saturated Fat Diet for Type 2 Diabetes Management
Posted November 07, 2014
Interview with NuSirt CEO Joe Cook, Jr: Improving Metformin Treatment, Part 1
Posted November 02, 2014
Exenatide a Noninsulin Addition for Patients Failing Basal Insulin
Posted October 23, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
If the U.S. Affordable Care Act is reversed in the new congress, what impact will that have on your patients?
CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control